Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy
- 31 January 1995
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 22 (1), 22-26
- https://doi.org/10.1016/0168-8278(95)80255-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis CJournal of Hepatology, 1994
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991
- Cellular Sources of Noncollagenous Matrix Proteins: Role of Fat-Storing Cells in FibrogenesisSeminars in Liver Disease, 1990
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- Serum hyaluronate in primary biliary cirrhosis—A biochemical marker for progressive liver damageHepatology, 1988
- Serum hyaluronate in liver diseases: Study by enzymoimmunological assayHepatology, 1986
- Increased serum levels of hyaluronate in liver diseaseHepatology, 1985
- Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liverExperimental Cell Research, 1983
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1981